menu

About
Ionis Innovation
- Overview
- Antisense Technology
- Optimizing Antisense
- Pipeline
- Ion-ARPA Initiative
Our Medicines
Patients & Community
- Overview
- Patient Resources
- Community Engagement
- Patient Experiences
Investors & media
- Overview
- Newsroom
  - Press Releases
  - Company Statements
  - InBriefs
  - Media Center
- Events
- Stock Information
  - Stock Quote & Chart
  - Analyst Coverage
  - Ownership Profile
- Financials
  - SEC Filings
  - Annual Reports
- Governance
  - Governance Documents
  - Committee Composition
  - RSU Holdings Guidelines
- Investor Resources
  - Investor FAQs
  - Contact Us
Careers
- Overview
- Working at Ionis
- Employee Spotlight
- Intern Program
- Post Doctoral Program

Investor contact

760-603-2331

Media contact

760-603-4679

January 23, 2023

Ionis’ statement about the FDA advisory committee meeting on tofersen